Literature DB >> 2329275

Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.

D S Tyler1, S D Stanley, C A Nastala, A A Austin, J A Bartlett, K C Stine, H K Lyerly, D P Bolognesi, K J Weinhold.   

Abstract

HIV-1-specific cell-mediated cytotoxicity (CMC) is a form of antibody-dependent cellular cytotoxicity (ADCC) in which HIV-1-specific antibodies arm NK cells directly to become cytotoxic for targets bearing HIV-1 antigenic determinants. This non-MHC-restricted cytotoxic activity is present in early stages of disease and declines markedly with disease progression. To understand the cellular and humoral factors contributing to the reduction in this activity, the conditions under which maximal arming of cells occurs was examined in vitro. With the use of a large patient cohort, a strong positive correlation was found between the capacity of a serum to direct lysis in standard ADCC assays and its ability to arm NK cells. Patients with minimal HIV-1-specific ADCC-directing antibodies exhibited low levels of CMC and were unable to arm normal effector cells in vitro. The lack of sufficient ADCC-directing antibodies was found to be one cause of defective CMC in some patients. Unlike asymptomatics, only a weak positive correlation was found between arming and ADCC with sera from AIDS patients, indicating that a factor other than absolute HIV-1 specific antibody titer was responsible for decreased CMC in this patient population. Another group of patients was found to have diminished CMC despite the presence of antibodies in the serum that were fully capable of arming normal effector cells to become cytotoxic for gp120-expressing targets. When compared with those of normal individuals, lymphocytes from seropositive patients mediated significantly reduced levels of cytotoxicity in ADCC and arming assays with the use of a high titered HIV-1-specific serum. In both assay systems, the magnitude and frequency of dysfunction in antibody-dependent cytolysis was found to be greater among AIDS patients than among asymptomatic individuals. The demonstration of both cellular and humoral defects in the ability of seropositive individuals to manifest ADCC reactivities strongly suggests that HIV-1 infection may significantly compromise the effectiveness of this potentially important cytolytic reactivity in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329275

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  Paediatric oncology in developing countries.

Authors:  G Prindull
Journal:  Eur J Pediatr       Date:  1991-08       Impact factor: 3.183

2.  Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.

Authors:  C-C Tang; G Isitman; J Bruneau; C Tremblay; N F Bernard; S J Kent; M S Parsons
Journal:  Clin Exp Immunol       Date:  2015-06-07       Impact factor: 4.330

3.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 4.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

5.  Changes in natural immunity during the course of HIV-1 infection.

Authors:  B G Brenner; C Gryllis; M Gornitsky; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

7.  Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals.

Authors:  C Gryllis; M A Wainberg; Z Bentwich; M Gornitsky; B G Brenner
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

Review 9.  Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Authors:  Margaret E Ackerman; Galit Alter
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

10.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.